Alto Neuroscience Investors: Lead Plaintiff Deadline Sept. 19, 2025.

Rosen Law Firm reminds investors who purchased Alto Neuroscience common stock in the IPO or between February 2, 2024, and October 22, 2024, of the September 19, 2025 lead plaintiff deadline. Investors may be entitled to compensation through a contingency fee arrangement. To join the Alto class action, visit https://rosenlegal.com/submit-form/?case_id=42321 or call Phillip Kim, Esq., at 866-767-3653 or email [email protected]. A class action lawsuit has already been filed.

Title: Rosen Law Firm Alerts Investors to Lead Plaintiff Deadline in Alto Neuroscience Class Action

NEW YORK, July 2, 2025 — Rosen Law Firm has reminded investors who purchased common stock of Alto Neuroscience, Inc. (NYSE: ANRO) during the initial public offering (IPO) or between February 2, 2024, and October 22, 2024, of the September 19, 2025 lead plaintiff deadline. Investors with losses in excess of $100,000 may be entitled to compensation through a contingency fee arrangement.

The class action lawsuit, which has already been filed, alleges that during the class period, defendants made materially false and misleading statements regarding Alto's business, operations, and prospects. Specifically, the offering documents and defendants made false or misleading statements and/or failed to disclose that:

1. ALTO-100 was less effective in treating major depressive disorder (MDD) than defendants had led investors to believe.
2. Accordingly, ALTO-100's clinical, regulatory, and commercial prospects were overstated.
3. As a result, Alto's business and/or financial prospects were overstated.
4. As a result, Alto's public statements were materially false and misleading at all relevant times.

When the true details entered the market, investors suffered damages.

Investors who wish to join the Alto class action can visit [https://rosenlegal.com/submit-form/?case_id=42321](https://rosenlegal.com/submit-form/?case_id=42321) or contact Phillip Kim, Esq., at 866-767-3653 or email [case@rosenlegal.com](mailto:case@rosenlegal.com). A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. The deadline to move the Court for lead plaintiff status is September 19, 2025.

Rosen Law Firm encourages investors to select qualified counsel with a proven track record in securities class actions. The firm has achieved significant settlements, including the largest ever against a Chinese company, and has been ranked in the top 4 by ISS Securities Class Action Services since 2013.

Reference List:

1. [Rosen Law Firm Press Release](https://www.prnewswire.com/news-releases/anro-deadline-anro-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-alto-neuroscience-inc-securities-fraud-lawsuit-302542395.html)
2. [Marketscreener News](https://www.marketscreener.com/news/anro-deadline-anro-investors-with-losses-in-excess-of-100k-have-opportunity-to-lead-alto-neuroscience-inc-securities-fraud-lawsuit-302542395.html)
3. [Pomerantz Law Firm Press Release](https://www.morningstar.com/news/globe-newswire/9518598/pomerantz-law-firm-announces-the-filing-of-a-class-action-against-alto-neuroscience-inc-and-certain-officers-anro)